Navigation Links
DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Date:7/8/2009

complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). Factors affecting the development and use of LPM(TM) are similar to those affecting orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Forms 10-Q and 10-K. Unless required by law, DOR assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.


'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
2. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
3. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
4. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
5. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
6. Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy
7. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
8. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
9. PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million
10. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
11. Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 23, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... first quarter 2015 results before the Nasdaq market opens ... a live conference call and webcast to discuss its financial ... 30, 2015 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1906 (US) or 785-424-1825 (International) ...
(Date:4/23/2015)... , April 23, 2015  Cryoport, Inc. (OTCBB: ... logistics solutions for the life sciences industry, today ... cryogenic logistics solutions within the animal husbandry market ... Farms to support the shipment of equine semen ... horse Stallions. Animal husbandry is ...
(Date:4/23/2015)... Bethlehem, PA (PRWEB) April 23, 2015 ... announce it is the first EMC® Enterprise Content ... on the entire EMC Documentum® for Life ... Glemser has proven knowledge and capabilities to provide ... Documentum-based, purpose-built solutions. , The EMC Documentum ...
(Date:4/23/2015)... NEW YORK , April 23, 2015 /PRNewswire/ ... development stage healthcare company, focuses on the development ... colorectal cancer. The company lead product includes PRP, ... as trypsinogen and chymotrypsinogen, as well as the ... It is also developing a combination of anti-cancer ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Glemser Earns Accreditation for Life Sciences Solution Suite 2Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
... April 25 /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,International, Inc. ... "the,Company"), a leading provider in the nutraceutical ... of organic nutritional food,products, supplements, and personal ... ("PRC"), today announced that it has formally ...
... WESTBROOK, Maine, April 25 IDEXX,Laboratories, Inc. (Nasdaq: ... of 2008 increased 18% to $249.1 million from $211.2 ... share ("EPS") for the,quarter ended March 31, 2008 were ... prior year. Non-GAAP adjusted diluted EPS for the first,quarter ...
... Therapeutics,Inc. (Nasdaq: CVTX ) today reported financial results for ... ended March 31, 2008, the Company reported a net loss,of ... net loss of $34.1,million, or $0.57 per share, for the ... per share, for the same quarter in 2007., For ...
Cached Biology Technology:China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 2China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 3IDEXX Laboratories Announces First Quarter Results 2IDEXX Laboratories Announces First Quarter Results 3IDEXX Laboratories Announces First Quarter Results 4IDEXX Laboratories Announces First Quarter Results 5IDEXX Laboratories Announces First Quarter Results 6IDEXX Laboratories Announces First Quarter Results 7IDEXX Laboratories Announces First Quarter Results 8IDEXX Laboratories Announces First Quarter Results 9IDEXX Laboratories Announces First Quarter Results 10IDEXX Laboratories Announces First Quarter Results 11IDEXX Laboratories Announces First Quarter Results 12IDEXX Laboratories Announces First Quarter Results 13IDEXX Laboratories Announces First Quarter Results 14IDEXX Laboratories Announces First Quarter Results 15IDEXX Laboratories Announces First Quarter Results 16IDEXX Laboratories Announces First Quarter Results 17CV Therapeutics Reports 2008 First Quarter Financial Results 2CV Therapeutics Reports 2008 First Quarter Financial Results 3CV Therapeutics Reports 2008 First Quarter Financial Results 4CV Therapeutics Reports 2008 First Quarter Financial Results 5
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... has published a paper today that is the most ... temperatures are having on the worlds coral reefs. ... Change and Ocean Acidification, co-authored by seventeen marine scientists ... will not survive the drastic increases in global temperatures ...
... Mass. -- A pioneering study of wild chimpanzees has ... experience menopause, rebutting previous studies of captive individuals which ... 35 to 40 years of age. Together with ... -- described this week in the journal Current Biology ...
... the Open Access publisher for Physics, Mathematics and ... CERN and DESY high-energy physics laboratories. Under ... charges for all research published by their investigators ... A. PMC Physics A is edited by ...
Cached Biology News:Immediate action needed to save corals from climate change 2Immediate action needed to save corals from climate change 3Wild chimpanzees appear not to regularly experience menopause 2Top physics laboratories sign up to open access with PhysMath Central 2
... 100% capped transcripts with the translation boosting ... of 100% capped (versus 40% to 80% ... in about 2 hours. mScript™ also features ... shown to be up to 50% more ...
... with Gateway™ Technology is designed to ... polyhedrin promoter. The expression cassette is ... DNA) by site-specific transposition (Tn7) in ... bacmid DNA is then used for ...
Immunogen: Synthetic peptide: M(1) C V P R S G L I L S(11) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Biology Products: